Quarterly ResultAug 12, 2026, 04:38 PM
Vyome Holdings Q2 Net Loss Widens to $1.7M; R&D Soars
AI Summary
Vyome Holdings reported a significant widening of its net loss to $1.65 million for the first six months of 2026, compared to $0.60 million in the prior year, primarily driven by a substantial increase in research and development expenses. Revenue also saw a sharp decline. Despite these financial challenges and a going concern warning, the company is actively advancing its clinical pipeline, including receiving FDA feedback for its lead program VT-1953 and entering a new in-licensing agreement.
Key Highlights
- Net loss attributable to owners widened to $(1,648,466) for H1 2026 from $(602,732) for H1 2025.
- Revenue decreased to $58,546 for H1 2026 from $248,535 for H1 2025.
- Research and development expenses surged to $1,173,128 for H1 2026 from $170,329 for H1 2025.
- Cash and cash equivalents increased to $7.89 million as of June 30, 2026, from $4.98 million at Dec 31, 2025.
- Vyome received FDA feedback on its VT-1953 pre-IND package and plans a Type C meeting.
- The company entered an in-licensing agreement with Impetis Biosciences for preclinical JAK inhibitor assets.
- Management noted a going concern risk but believes it has sufficient funds for 12 months.
Price Impact
More from HIND
Quarterly ResultMay 29, 8:51 AM
Vyome Reports Q1 Results, In-licenses JAK Inhibitors, Files for FDA Orphan Drug
Quarterly ResultMay 12, 4:08 PM
Vyome Holdings Q1 Revenue $31.6K, Net Loss $985.5K; Cash $8.8M
Corporate ActionApr 29, 4:43 PM
Vyome Holdings (HIND) Decreases Authorized Common Stock to 50M Shares